Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting Trop-2 in cancer: Recent research progress and clinical application
Shuying Qiu, Jianping Zhang, Zhuo Wang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 4, pp. 188902-188902
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Recent advances in targeted strategies for triple-negative breast cancer
Shuangli Zhu, Yuze Wu, Bin Song, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 113
TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
Caili Xu, Min Zhu, Qian Wang, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 51
Modulating autophagy to boost the antitumor efficacy of TROP2-directed antibody-drug conjugate in pancreatic cancer
Caili Xu, Xiting Huang, Qinchao Hu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 180, pp. 117550-117550
Open Access | Times Cited: 17
Trop2-targeted therapies in solid tumors: advances and future directions
Xinlin Liu, Leina Ma, Jiyixuan Li, et al.
Theranostics (2024) Vol. 14, Iss. 9, pp. 3674-3692
Open Access | Times Cited: 11
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Taizo Uchimoto, Takuya Matsuda, Kazumasa Komura, et al.
Targeted Oncology (2024) Vol. 19, Iss. 4, pp. 635-644
Closed Access | Times Cited: 8
Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs
Yizhi Jiang, Haiting Zhou, Junxia Liu, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 652-652
Open Access | Times Cited: 7
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors
Taizo Uchimoto, Shuya Tsuchida, Kazumasa Komura, et al.
Targeted Oncology (2024) Vol. 19, Iss. 3, pp. 401-410
Closed Access | Times Cited: 5
Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions
Yujun Tong, Xiaobing Fan, Huan Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Trophoblast cell surface antigen 2 expression in scalp basal cell carcinomas: does it differ from the facial basal cell carcinomas location?
Fatma Alzahraa Abdelsalam Elkhamisy, Ahmed Naeem Eesa, Nadia Ahmed Abd El-Moeze
Egyptian Journal of Dermatology and Venerology (2025) Vol. 45, Iss. 1, pp. 41-48
Closed Access
Trophoblast Cell Surface Antigen Imprinted Polymer Nanoparticles for Breast Cancer Therapy
Lila Louadj, Perla Benghouzi, Romain Morichon, et al.
ACS Applied Nano Materials (2025) Vol. 8, Iss. 1, pp. 329-339
Closed Access
Beyond failure of endocrine-based therapies in HR+/HER2 negative advanced breast cancer: what before chemotherapy? A glimpse into the future.
Rosalba Torrisi, R. Gerosa, Chiara Miggiano, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 208, pp. 104634-104634
Closed Access
Mapping the patent landscape of TROP2-targeted biologics through deep learning
X. D. Yu, Yao Jin, Kunmeng Liu, et al.
Nature Biotechnology (2025) Vol. 43, Iss. 4, pp. 491-500
Closed Access
The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts
Han Liu, Hongye Zeng, Xiaojing Qin, et al.
Protein & Cell (2025)
Open Access
Contemporary management of advanced gastric and gastroesophageal adenocarcinomas
Jane E. Rogers, Jaffer A. Ajani
Expert Review of Anticancer Therapy (2025), pp. 1-7
Closed Access
Differences in HER2-0 and HER2-low Breast Cancer: Androgen Receptor and Programmed Death Ligand 1 as Predictive Factors
Xiaoqi Zhang, Ciqiu Yang, Yitian Chen, et al.
Journal of Breast Cancer (2025) Vol. 28, Iss. 1, pp. 23-23
Open Access
Lines of Therapy for Locally Advanced/Metastatic Urothelial Carcinoma: The New Paradigm
Oluseyi Abidoye, Prateek Jain, Parminder Singh
JCO Oncology Practice (2025)
Closed Access
TROP2 expression and therapeutic targeting in uterine carcinosarcoma
Sara Moufarrij, Higinio Dopeso, David N. Brown, et al.
Gynecologic Oncology (2025) Vol. 197, pp. 129-138
Closed Access
Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back
Valentina Rossi, Alessandra Turati, Antonio Rosato, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
The Relationship between Trop-2, Chemotherapeutic Drugs, and Chemoresistance
Tomas Koltai, Larry Fliegel
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 87-87
Open Access | Times Cited: 5
Antibody - Drug Conjugates as a Novel Therapeutic Modality to Treat Recurrent Refractory Germ Cell Tumors.
Natália Udvorková, Adriana Fekiačová, Kristína Majtánová, et al.
AJP Cell Physiology (2024) Vol. 327, Iss. 2, pp. C362-C371
Closed Access | Times Cited: 1
Antibody–drug conjugates treatment of small cell lung cancer: advances in clinical research
Yuan Meng, Xuerui Wang, Jie Yang, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Survey on adverse events associated with drug therapy for breast cancer patients
Fumikata Hara, Reiko Nagasaki, Reiko Minami, et al.
BMC Women s Health (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Incidence of antibody–drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis
Ping Yang, Hengheng Zhang, Jinming Li, et al.
Therapeutic Advances in Drug Safety (2024) Vol. 15
Open Access | Times Cited: 1
Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors
Dan Morgenstern‐Kaplan, Samuel A. Kareff, Asaad Trabolsi, et al.
The Oncologist (2024) Vol. 29, Iss. 11, pp. e1480-e1491
Open Access
Survey on adverse events associated with drug therapy for breast cancer patients
Fumikata Hara, Reiko Nagasaki, Reiko Minami, et al.
(2024)
Closed Access
Page 1 - Next Page

Scroll to top